Pharmaceutical

TT-01488 by TransThera Sciences (Nanjing) for Mantle Cell Lymphoma: Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Mantle Cell Lymphoma.

May 17, 2024 - 04:00
TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Mantle Cell Lymphoma.
Read the original article

Tags:

Previous Article

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus A Infections: Like...

Next Article

MRNA-1365 by Moderna for Human Metapneumovirus Infections: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Covid-19 increases risk of developing autoimmune disease, but vaccination helps, large study shows

Covid-19 increases risk of developing autoimmune diseas...

Mar 4, 2024

AstraZeneca champions early kidney disease diagnosis with modelling data

AstraZeneca champions early kidney disease diagnosis wi...

Jun 12, 2024

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosim...

Jul 24, 2024